vimarsana.com

Latest Breaking News On - Sarepta therapeutics company profile - Page 1 : vimarsana.com

Mizuho Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $179 00

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lifted by Mizuho from $145.00 to $179.00 in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. UBS Group raised their price […]

Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179 00

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 36.25% from the stock’s previous close. A number […]

Needham & Company LLC Reaffirms Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $166.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 26.81% […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.